INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) has several histologic subtypes, which have shown potential for differential clinical outcomes. Our study objective was to evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN).
METHODS: We queried the National Cancer Data Base (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) for patients with T1a RCC who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS. Our adjusted model included age, sex, race/ethnicity, insurance status, median income, proportion without high school diploma, urbanicity, Charlson-Deyo index, tumor grade, and facility volume.
RESULTS: Of the 52,245 T1a masses that met inclusion criteria, 51.1% were clear cell, followed by papillary (34.8%), chromophobe (11.8%), cystic (1.8%), sarcomatoid (0.4%) and collecting duct (0.2%). PN was performed in 51%, RN in 31%, and 18% had PA. Kaplan Meier curves demonstrated differences in survival by histology among clear cell, papillary, chromophobe, and cystic subtypes (all p<0.001), but not for sarcomatoid (p[0.110) There is a fundamental lack of knowledge regarding patients with muscle-invasive bladder cancer (MIBC) that are left untreated.This is an important point when counseling patients. In an effort to address this void, we leveraged the Stockholm cohort for patients with MIBC who did not receive any additional treatment after TURBT, and compared their outcomes with patients who received treatment with curative intent.
METHODS: All patients diagnosed with bladder cancer during 1995-1996 in the Stockholm county were collected in a population based cohort consisting of 735 patients. 126 patients diagnosed with non-metastatic MIBC were identified. Kaplan-Meier and cumulative incidence curves were used to evaluate overall survival (OS) and cancer specific mortality (CSM). A multivariable Cox regression was fitted to predict OS; whereas a competing risks regression was adopted for the prediction of CSM, after accounting for other cause mortality (OCM). Analyses were adjusted for age at diagnosis, sex, clinical stage, tumor stage and treatment (yes vs. no).
RESULTS: Overall, 64 (51%) patients did not receive any treatment because of advanced age or comorbidity, whereas 62 (49%) received treatment with curative intent, as either radical cystectomy: 47 or radiation therapy: 15. For untreated patients, median (IQR) age at diagnosis was 79 (63-83) yrs vs. 69 (63-74) in the treated group (p<0.001). The median follow-up for survivors was 14.4 yrs; 109 patients died during follow-up, 89 of them experienced CSM. The 5-yr OS rate for untreated patients was 5% (95%CI: 1-12%) vs. 48% (95% CI: 36-60%) of treated patients. Patients not receiving any treatment had a 5-yr cumulative incidence of CSM of 86% (95%CI: 75-94%) vs. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e923
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